HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF-α) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis

Table 3

Meta-analysis on HBV reactivation among patients with rheumatoid arthritis treated with biologic agents.

(a)  

First author, year	Number of patients	HBV reactivation (𝑛)	HBV reactivation (%)	CI 95%	Weight (%)
All  patients
Caporali et al., 2010 [11]	59	0	0.0	0.0–6.1	18.4
Lan et al., 2011 [15]	88	6	6.8	3.2–14.1	20.6
Mori, 2011 [16]	32	1	3.1	0.5–15.7	14.5
Ryu et al., 2012 [17]	22	0	0.0	0.0–14.9	12.1
Tamori et al., 2011 [18]	44	0	0.0	0.0–8.0	16.6
Urata et al., 2011 [19]	52	5	9.6	4.2–20.6	17.7
Pooled estimate			3.3	0.7–7.5	100.0

Heterogeneity chi-squared = 13.37 (d.f. = 5) 𝑃 = 0.020.
𝐼-squared (variation in ES attributable to heterogeneity) = 62.6%.

(b)  

First author, year	Number of patients	HBV reactivation (𝑛)	HBV reactivation (%)	CI 95%	Weight (%)
Patients  with  overt  chronic  HBV  infection
Lan et al., 2011 [15]	18	5	27.8	12.5–50.9	49.5
Ryu et al., 2012 [17]	22	0	0.0	0.0–14.9	50.5
Pooled estimate			10.7	1.4–50.2	100.0

Heterogeneity chi-squared = 8.91 (d.f. = 1) 𝑃 = 0.003.
𝐼-squared (variation in ES attributable to heterogeneity) = 88.8%.

(c)  

First author, year	Number of patients	HBV reactivation (𝑛)	HBV reactivation (%)	CI 95%	Weight (%)
Patients  with  occult  HBV  infection
Caporali et al., 2010 [11]	59	0	0.0	0.0–6.1	21.5
Lan et al., 2011 [15]	70	1	1.4	0.2–7.7	22.8
Mori, 2011 [16]	31	1	3.2	0.6–16.2	16.3
Tamori et al., 2011 [18]	42	0	0.0	0.0–8.4	18.8
Urata et al., 2011 [19]	52	5	9.6	4.2–20.6	20.5
Pooled estimate			2.6	0.4–6.6	100.0

Heterogeneity chi-squared = 9.80 (d.f. = 4) 𝑃 = 0.044.
𝐼-squared (variation in ES attributable to heterogeneity) = 59.2%.